PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 228 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $408,100 | -89.4% | 10,000 | -90.0% | 0.15% | -92.5% |
| Q4 2022 | $3,861,000 | -62.8% | 100,000 | -48.7% | 1.99% | -67.4% |
| Q3 2022 | $10,372,000 | +1.7% | 195,000 | +11.4% | 6.09% | +3.2% |
| Q2 2022 | $10,203,000 | -34.8% | 175,000 | -14.6% | 5.90% | -20.3% |
| Q1 2022 | $15,646,000 | +8.3% | 205,000 | -14.6% | 7.40% | +24.7% |
| Q4 2021 | $14,441,000 | -31.2% | 240,000 | -36.0% | 5.94% | -10.5% |
| Q3 2021 | $21,000,000 | -3.9% | 375,000 | +4.2% | 6.63% | +7.2% |
| Q2 2021 | $21,845,000 | -43.3% | 360,000 | -34.5% | 6.19% | -21.7% |
| Q1 2021 | $38,550,000 | -11.6% | 550,000 | -25.2% | 7.91% | -12.9% |
| Q4 2020 | $43,593,000 | +10.7% | 735,000 | +12.2% | 9.08% | -25.2% |
| Q3 2020 | $39,379,000 | +7.2% | 655,000 | -6.4% | 12.14% | +18.7% |
| Q2 2020 | $36,729,000 | +99.2% | 700,000 | +27.3% | 10.23% | +46.4% |
| Q1 2020 | $18,442,000 | -33.7% | 550,000 | -11.6% | 6.98% | +9.9% |
| Q4 2019 | $27,813,000 | -5.7% | 622,500 | -19.7% | 6.36% | -17.3% |
| Q3 2019 | $29,504,000 | +9.1% | 775,000 | +24.0% | 7.69% | -6.5% |
| Q2 2019 | $27,044,000 | +122.1% | 625,000 | +95.3% | 8.22% | +70.1% |
| Q1 2019 | $12,179,000 | +65.2% | 320,000 | +113.3% | 4.84% | +129.7% |
| Q3 2018 | $7,373,000 | +21.1% | 150,000 | -21.1% | 2.10% | +3.2% |
| Q2 2018 | $6,090,000 | +64.7% | 190,000 | +60.1% | 2.04% | +15.9% |
| Q1 2018 | $3,698,000 | -74.3% | 118,702 | -62.3% | 1.76% | -77.6% |
| Q4 2017 | $14,380,000 | +53.2% | 315,000 | +26.0% | 7.85% | +36.6% |
| Q3 2017 | $9,388,000 | -8.5% | 250,000 | +16.3% | 5.75% | -4.0% |
| Q2 2017 | $10,256,000 | -15.1% | 215,000 | -18.9% | 5.99% | -20.7% |
| Q1 2017 | $12,084,000 | +37.0% | 265,000 | -2.9% | 7.55% | +21.1% |
| Q4 2016 | $8,818,000 | -68.9% | 273,000 | -65.9% | 6.24% | +40.0% |
| Q3 2016 | $28,328,000 | +342.0% | 800,000 | +321.1% | 4.46% | +81.2% |
| Q2 2016 | $6,409,000 | – | 190,000 | – | 2.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |